Viavi Solutions (VIAV): Evaluating Valuation Following Strong Earnings, Guidance, and New Calnex Partnership

Viavi Solutions (VIAV) reported solid revenue gains in its latest quarterly results and shared strong guidance for the upcoming quarter. The company also announced a new partnership with Calnex Solutions, which expands its telecom test solution offerings.

See our latest analysis for Viavi Solutions.

Viavi Solutions’ upbeat earnings guidance and new partnership with Calnex Solutions appear to have energized investors, with the stock posting a dramatic 45% share price return in the past month and up 76% year-to-date. While total shareholder return over the past year reached 69%, recent momentum suggests that confidence in the company’s growth potential is building rapidly.

If you’re interested in seeing how other technology players are taking advantage of similar industry shifts, our curated list highlights some of the most compelling opportunities right now: See the full list for free.

With such impressive recent gains, investors now face a crucial question: does Viavi Solutions remain undervalued with more upside ahead, or has the market already priced in the company’s growth potential?

Advertisement

Most Popular Narrative: 22% Overvalued

With the latest fair value estimate at $14.57 per share and the stock closing at $17.81, the narrative suggests shares have surged past what bullish analysts view as justified by fundamentals. This sets the stage for a closer look at the assumptions driving the valuation call.

Viavi is experiencing robust and sustained demand across the data center ecosystem, with customers updating optical connectivity to 400G, 800G, and now 1.6T. This enables multi-year upgrade cycles and expands its total addressable market, which should drive structural revenue growth through 2026 and beyond.

Read the complete narrative.

Want to know the growth blueprint behind this high valuation? The key element of this narrative is record-breaking earnings and a future profit multiple usually associated with tech leaders. Interested in which bold financial projections support that price target? Dive deeper to see the surprising numbers that drive this fair value calculation.

Result: Fair Value of $14.57 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent weakness in Viavi’s wireless test segment or unexpected supply chain disruptions could quickly challenge the current positive growth narrative.

Find out about the key risks to this Viavi Solutions narrative.

Another View: Multiples Raise Red Flags

A quick check on Viavi’s price-to-sales ratio shows it is trading at 3.5x, which is notably higher than both the US Communications industry average of 2.1x and the peer average of 2.4x. Even its current ratio sits below the fair ratio of 5.6x that our regression suggests the market could move toward. However, this gap highlights real valuation risk if optimism fades. Does the premium mean upside is still on the table, or are investors paying up for peak momentum?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:VIAV PS Ratio as at Nov 2025
NasdaqGS:VIAV PS Ratio as at Nov 2025

Build Your Own Viavi Solutions Narrative

If you want to interpret these numbers differently or see fresh angles in the data, crafting your own investment story is quick and straightforward. Do it your way

A great starting point for your Viavi Solutions research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Don't limit your investing to just one opportunity when there are so many under-the-radar gems and growth stories waiting to be found. Make smarter moves for your portfolio by checking out these handpicked ideas:

  • Tap into the fast-evolving world of artificial intelligence when you check out these 25 AI penny stocks, featuring innovative companies that are shaping tomorrow’s tech landscape.
  • Boost your portfolio’s income potential by reviewing these 16 dividend stocks with yields > 3%, a lineup of reliable stocks that offer strong dividends and steady growth prospects.
  • Spark your curiosity and see what’s next in digital transformation through these 82 cryptocurrency and blockchain stocks, where cutting-edge blockchain and crypto businesses are redefining entire industries.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:VIAV

Viavi Solutions

Provides network test, monitoring, and assurance solutions for telecommunications, cloud, enterprises, first responders, military, aerospace, and critical infrastructures in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa.

High growth potential with mediocre balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
48 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
188 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0